ACCEL Lite: AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients with Acute Myocardial Infarction Without Diabetes

Nov 17, 2023   |  Alison Bailey, MD, FACC; Stefan K James, MD, PhD; Laxmi S. Mehta, MD, FACC

Podcast
Print
Font Size
A
A
A

Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.

Related References:

  1. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Björkgren I, Johansson PA, Langkilde AM, Ridderstråle W, Parvaresh Rizi E, Deanfield J, Oldgren J. Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. Am Heart J. 2023 Aug 25:S0002-8703(23)00207-7. doi: 10.1016/j.ahj.2023.08.008. Epub ahead of print. PMID: 37648579.
Subscribe to the ACCEL Lite Podcast

Clinical Topics: Acute Coronary Syndromes, Heart Failure and Cardiomyopathies

Keywords: ACCELLite, AHA23, American Heart Association, Myocardial Infarction, Diabetes Mellitus


< Back to Listings